Kositchaiwat C et al. |
Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616168
|
Datta S et al. |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963080
|
Tepes B et al. |
Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421880
|
Calvet X et al. |
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421884
|
Louw JA et al. |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768531
|
Laine L et al. |
Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768532
|
Tomita T et al. |
Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966543
|
Vakil N et al. |
Seven-day therapy for Helicobacter pylori in the United States. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15225176
|
Basset C et al. |
Helicobacter pylori infection: anything new should we know? |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15335411
|
Mason J et al. |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876711
|
Georgopoulos SD et al. |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876712
|
Goddard AF et al. |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233187
|
Pilotto A et al. |
The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10233191
|
Miyaji H et al. |
Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663841
|
Wong BC et al. |
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:11069326
|
Lionetti E et al. |
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17032283
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Gisbert JP et al. |
Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:16268980
|
Miwa H et al. |
Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823158
|
Armuzzi A et al. |
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11148433
|